1 |
Taghizadeh MJ, Khodadadi S, Zamanifard S. Evaluation of Drugs and Strategies for Treating Coronary Artery Ectasia: Update and Future Perspective. Jundishapur J Chronic Dis Care 2022;In Press. [DOI: 10.5812/jjcdc-123301] [Reference Citation Analysis]
|
2 |
Wang X, Wang G, Shang J, Pan H, Zhang XA, Zhou F. Immunosuppressive therapies adversely affect blood biochemical parameters in patients with inflammatory bowel disease: a meta-analysis. J Int Med Res 2019;47:3534-49. [PMID: 31364448 DOI: 10.1177/0300060519864800] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
3 |
Li Y, Ren JA, Wang GF, Gu GS, Wu XW, Liu S, Ren HJ, Hong ZW, Li JS. Impaired Coagulation Status in the Crohn's Disease Patients Complicated with Intestinal Fistula. Chin Med J (Engl) 2018;131:567-73. [PMID: 29483391 DOI: 10.4103/0366-6999.226072] [Reference Citation Analysis]
|
4 |
Zhang J, Guo Z, Yang W, Zhu Z, Kong W, Zheng S, Jiang L, Fei X, Chen Y, Liu J. D-Dimer levels are correlated with disease activity in Crohn's patients. Oncotarget 2017;8:63971-7. [PMID: 28969045 DOI: 10.18632/oncotarget.19250] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
|
5 |
Peyrin-Biroulet L, Van Assche G, Gómez-Ulloa D, García-Álvarez L, Lara N, Black CM, Kachroo S. Systematic Review of Tumor Necrosis Factor Antagonists in Extraintestinal Manifestations in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol 2017;15:25-36.e27. [PMID: 27392760 DOI: 10.1016/j.cgh.2016.06.025] [Cited by in Crossref: 82] [Cited by in F6Publishing: 68] [Article Influence: 13.7] [Reference Citation Analysis]
|